3rd Quarter - Report

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Firm
Client
Income
—
Expenses
$1,740,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
STEPHANIE A. DYSON New —
LISA NELSON New —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2071 (117th), H.R. 1319 (117th), S. 908 (117th), H.R. 2139 (117th), H.R. 5237 (117th), S. 464 (117th)

Trade (domestic/foreign) TRD

International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); U.S. Trade Representative (USTR)

Taxation/Internal Revenue Code TAX

Proposed policies regarding corporate tax reform regarding all bio-pharmaceutical related provisions. No bill number Import Taxes regarding all bio-pharmaceutical related provisions. No bill number.

LobbyistCovered position, as disclosed
JOHN DEOUDES —
LANE PENRY —
PAUL ANTHONY WILLIAMS —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2873 (117th), S. 1435 (117th)

Medicare/Medicaid MMM

H.R. 2163 - To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health regarding all bio-pharmaceutical related provisions H.R. 19 - Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes regarding all bio-pharmaceutical related provisions H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.

LobbyistCovered position, as disclosed
THOMAS BRUNET —
JOHN DEOUDES —
STEPHANIE A. DYSON New —
LISA NELSON New —
KATHRYN NOVARIA —
LANE PENRY —
RICARDO SANCHEZ ORTEGON —
PAUL ANTHONY WILLIAMS —

Contacted: SENATE; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (117th), H.R. 1319 (117th), S. 908 (117th), H.R. 2071 (117th), H.R. 4385 (117th), H.R. 2139 (117th), H.R. 5237 (117th), H.R. 19 (117th), H.R. 2163 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.